Jikei Optimal Insulin Therapy in Type 2 Diabetes
|ClinicalTrials.gov Identifier: NCT00348231|
Recruitment Status : Unknown
Verified June 2006 by Jikei University School of Medicine.
Recruitment status was: Recruiting
First Posted : July 4, 2006
Last Update Posted : September 1, 2006
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2||Drug: dual-action insulin analog||Not Applicable|
The current insulin therapy is divided into the conventional insulin therapy (1~2 injections per day) and the intensive insulin therapy (3~4 injections per day). The kinetics of exogenous insulin in the intensive insulin therapy imitate the kinetics of insulin secretion in a healthy person. A previous large clinical study (e.g. DCCT, Kumamoto study, etc.) suggested that intensive insulin therapy prevented microangiopathy and macroangiopathy, and inhibited progression of them, however many patients chose conventional insulin therapy because many hoped that they injected insulin as few as possible. The patients thought that their life styles were disturbed by many times of insulin injection.
The current dual-acting insulin made from insulin as part modified by protamine is able to suppress postprandial hyperglycemia. The new insulin may possibly have the kinetics of insulin in the patient who uses insulin as the intensive insulin therapy. Moreover, the patients will receive the insulin therapy easily if the times of insulin injection are fewer. It may lead to perform the more effective insulin therapy to search for the optimal insulin therapy in induction in type 2 diabetes.
comparison:HbA1c, glycated albumin, IMT, lipid profile,body weight, daily profile of blood glucose,between the conventional insulin therapy and the intensive insulin therapy.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||November 2004|
|Study Completion Date :||August 2006|
- daily profile of blood glucose
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00348231
|Contact: Yumi Miyashita, MD||+081334331111 ext firstname.lastname@example.org|
|The Jikei university school of medicine division of diabetes and endoclinology dept. of internal medicine||Recruiting|
|Tokyo, Japan, 1058461|
|Contact: Yumi Miyawshita, MD +081334331111 ext 3249 email@example.com|
|Principal Investigator:||Yumi Miyashita, MD||The Jikei University School of Medicine|